A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. (Q38379114)
Jump to navigation
Jump to search
scientific article published on 23 July 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. |
scientific article published on 23 July 2016 |
Statements
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors (English)
J E Grilley-Olson
A Fasolo
M Cornfeld
L Cartee
A R Abdul Razak
L-A Stayner
Y Wu
R Greenwood
R Singh
C B Lee
J Bendell
H A Burris
G Del Conte
C Sessa
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference